References
- Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol. 2003;14:2199–2210
- Bonventre JV, Zuk A. Ischemic acute renal failure: An inflammatory disease? Kidney Int. 2004;66:480–485
- Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–2333
- Burne-Taney MJ, Yokota N, Rabb H. Persistent renal and extrarenal immune changes after severe ischemic injury. Kidney Int. 2005;67:1002–1009
- Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int. 2004;66:486–491
- Cook HT. The origin of renal fibroblasts and progression of kidney disease. Am J Pathol. 2010;176:22–24
- Azuma H, Nadeau K, Takada M, et al. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation. 1997;64:190–197
- Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1456
- Li JX, Li P, Tezuka Y, et al. Three phenylethanoid glycosides and an iridoid glycoside from Picrorrhiza scrophulariiflora. Phytochemistry. 1998;48:537–542
- Zou LC, Zhu TF, Xiang H, et al. New secoiridoid glycosides from the roots of Picrorrhiza scrophulariiflora. Molecules. 2008;13:2049–2057
- Li Q, Li Z, Xu XY, et al. Neuroprotective properties of Picroside II in a rat model of focal cerebral ischemia. Int J Mol Sci. 2010;11:4580–4590
- Feitoza CQ, Goncalves GM, Semedo P, et al. Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med. 2008;14:724–730
- Cao Y, Liu JW, Yu YJ, et al. Synergistic protective effect of Picroside II and NGF on PC12 cells against oxidative stress induced by H2O2. Pharmacol Rep. 2007;59:573–579
- Smit HF, Kroes BH, van den Berg AJ, et al. Immunomodulatory and anti-inflammatory activity of Picrorrhiza scrophulariiflora. J Ethnopharmacol. 2000;73:101–109
- Du X, Hu X, Wei J. Anti-inflammatory effect of exendin-4 post conditioning during myocardial ischemia and reperfusion. Mol Biol Rep. 2014;41:3853–3857
- Feitoza CQ, Goncalves GM, Semedo P, et al. Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med. 2008;14:724–730
- Lonnemann G, Shapiro L, Engler-Blum G, et al. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int. 1995;47:837–844
- Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;60:2118–2128
- Stahl PJ, Felsen D. Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: Implications for fibrosis in kidney disease. Am J Pathol. 2001;159:1187–1192
- Crisman JM, Richards LL, Valach DP, et al. Chemokine expression in the obstructed kidney. Exp Nephrol. 2001;9:241–248
- Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: Role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999;56:571–580
- Nguyen TQ, Goldschmeding R. Bone morphogenetic protein-7 and connective tissue growth factor: Novel targets for treatment of renal fibrosis? Pharm Res. 2008;25:2416–2426
- Damiao MJ, Bertocchi AP, Monteiro RM, et al. The effects of rapamycin in the progression of renal fibrosis. Transplant Proc. 2007;39:457–459
- Terzi F, Maunoury R, Colucci-Guyon E, et al. Normal tubular regeneration and differentiation of the post-ischemic kidney in mice lacking vimentin. Am J Pathol. 1997;150:1361–1371